Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) EBITDA (2016 - 2025)

Dare Bioscience's EBITDA history spans 8 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, EBITDA rose 73.67% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$13.4 million, down 224.93%, while the annual FY2025 figure was -$13.4 million, 224.93% down from the prior year.
  • EBITDA reached -$1.5 million in Q4 2025 per DARE's latest filing, up from -$3.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $12.9 million in Q2 2024 to a low of -$15.8 million in Q4 2022.
  • Average EBITDA over 5 years is -$5.9 million, with a median of -$7.0 million recorded in 2022.
  • Peak YoY movement for EBITDA: tumbled 3261.62% in 2023, then skyrocketed 246.99% in 2024.
  • A 5-year view of EBITDA shows it stood at -$9.5 million in 2021, then tumbled by 65.47% to -$15.8 million in 2022, then skyrocketed by 68.29% to -$5.0 million in 2023, then decreased by 11.47% to -$5.6 million in 2024, then soared by 73.67% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's EBITDA are -$1.5 million (Q4 2025), -$3.6 million (Q3 2025), and -$4.0 million (Q2 2025).